Regeneron Pharmaceuticals Inc (NASDAQ: REGN) faced Friday’s failure in a trial that evaluated its REGN-COV2 antibody cocktail in patients with COVID-19 hospitalized.
What happened: An independent data monitoring committee recommended that continued enrollment of patients requiring high-flow oxygen or mechanical ventilation should be halted, citing a potential safety signal and a risk profile. ro-benefits are detrimental at this time, Regeneron said on Friday.
The Committee recommends that admission be continued for hospitalized patients who need low or no oxygen flow, stating that a benefit-risk is acceptable in these groups.
IDMC has sought to make modifications in patient admission trials.
It also suggests that outpatient testing can be conducted without modification.
Related Links: Daily Biotechnology Pulse: Novavax Vaccine Data, Axovant Flag Delay in Parkinson’s Study, 2 Biotechnology that Causes Wall Street to Launch
Why is it important: Regeneron has an FDA pending emergency use license application for REGN-COV2 in a mild to moderate outpatient coronavirus with a high risk of poor outcome.
Regeneron’s COVID-19 pipeline came to prominence after an investigative antibody cocktail was handed over to President Donald Trump to treat his COVID-19 infection.
Eli Lilly and Co (NYSE: LLY) had to suspend the end-stage study of candidate bamlanivimab antibody therapy in hospitalized severe COVID-19 patients.
REGN price action: At the last check, shares of Regeneron fell 2.49% to $ 541.97.
Related Links: Last week on biotechnology: Kala FDA’s Decision, Merck & Pfizer Income, Vaccine Update and IPO
More From Benzinga
© 2020 Benzinga.com. Benzinga does not provide investment advice. All Rights Reserved.